← Back to Clinical Trials
Recruiting Phase 4 NCT05709626

PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition ST-segment Elevation Myocardial Infarction (STEMI)
Sponsor Kindai University
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 2,258
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-02-28
Completion 2025-01-04
Interventions
No aspirin (Prasugurel monotherapy)12-month DAPT

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).

Eligibility Criteria

Inclusion Criteria: * Patients scheduled for primary PCI with everolimus-eluting stent (PtCr-EES, SYNERGYTM) * STEMI patients * Patients who can continue dual antiplatelet therapy with aspirin and a P2Y12 inhibitor for 12 months Exclusion Criteria: * Patients taking anticoagulants * Patients under 18 years old * Patients with less than 1 year prognosis * Patients participating in other intervention studies

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI) TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}